RUNX1 and myelodysplastic syndrome: In therapy-related MDS, RUNX1 mutations are found in 8%–23% of cases and often in patients progressing to AML (7). These mutations, primarily located in the DNA-binding RUNT domain, typically result in the loss of RUNX1 function due to the removal of essential residues for binding (17).